Q1'23 Earnings Call Presentation November 1, 2022 Agenda Alessandro Maselli, President & Chief Executive Officer • Q1'23 highlights • FY'23 growth drivers Thomas Castellano, Senior VP & Chief Financial Officer • Q1'23 financial performance • Capitalization review • Updated guidance Question & Answer Session 2 Disclaimer Statement Forward-Looking Statements This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact, are, or may be deemed ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) _____________________________ Catalent, Inc. (Exact name of registrant as specifi ...

Financial Data and Key Metrics Changes - Fiscal 2022 net revenue was $4.83 billion, growing organically in constant currency by 20% compared to the prior fiscal year [8] - Adjusted EBITDA for the year was $1.29 billion, reflecting constant currency organic growth of 28% compared to fiscal 2021, with an adjusted EBITDA margin increase to 26.6% [8][39] - Fourth quarter revenue was $1.31 billion, increasing 10% as reported or 15% in constant currency compared to the fourth quarter of fiscal 2021 [9] - Fourth quarter adjusted net income was $215 million or $1.19 per diluted share, up from $1.16 per diluted share in the corresponding prior year period [40] Business Line Data and Key Metrics Changes - Biologics segment net revenue in Q4 was $667 million, increasing 14% compared to the fourth quarter of 2021, driven by demand in cell and gene therapy [28] - Softgel and Oral Technologies segment net revenue was $350 million, increasing 22% compared to the fourth quarter of fiscal 2021, with the acquisition of Bettera contributing significantly to growth [32][33] - Oral and Specialty Delivery segment net revenue grew 11%, with segment EBITDA up 27% over the fourth quarter of last year, driven by demand for Zydis offerings [35] - Clinical Supply Services segment posted net revenue of $104 million, representing 4% growth over the fourth quarter of fiscal 2021 [36] Market Data and Key Metrics Changes - The backlog for the Clinical Supply Services segment was $540 million, up from $529 million at the end of the last quarter and up 10% from June 30, 2021 [37] - The company expects long-term net revenue growth for the Pharma and Consumer Health segment to be 6% to 10%, with the Biologics segment expected to grow at 10% to 15% [12][13] Company Strategy and Development Direction - The company has reorganized its structure, reducing operating segments from four to two, focusing on Biologics and Pharmaceuticals & Consumer Health to enhance customer access to services [10][11] - The acquisition of Metrics Contract Services is expected to accelerate growth in the high drug manufacturing sector, with anticipated revenue growth comparable to the segment's projected overall long-term growth of 6% to 10% [19][21] - The company aims to achieve a 30% EBITDA margin by fiscal 2026, despite current challenges from inflation and supply chain issues [60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving fiscal 2023 organic growth in line with the long-term growth rate of 8% to 10%, despite a decline in COVID-related revenue [15][16] - The company anticipates that non-COVID business will grow organically by more than 25% at constant currency due to expansions and efficiencies in existing assets [17] - Management acknowledged ongoing supply chain challenges and inflationary pressures but remains optimistic about the company's growth strategy and market position [25] Other Important Information - The company reported a net leverage ratio of 2.9x as of June 30, 2022, slightly below the long-term target of 3.0x [41] - Capital expenditures as a percentage of revenue were 14% in fiscal 2022, with expectations for a similar range in fiscal 2023 [45][46] Q&A Session Summary Question: Can you provide insights on the margin headwinds and the impact of facility remediation? - Management confirmed that FX impacts are significant, with EBITDA being more affected than revenue, and ongoing remediation efforts in Brussels are factored into guidance [54][55][56] Question: What changes can customers expect from the new operating structure? - The new structure aims to reduce internal barriers and increase the share of services purchased by existing customers, enhancing commercial synergies [61][62] Question: What is the expected range of COVID-related revenue decline for 2023? - Management indicated a two-thirds reduction in COVID-related volumes, with minimal variability expected around this assumption [69][70] Question: How is the company addressing supply chain challenges? - Supply chain challenges are primarily impacting the consumer health side, with management actively seeking to offset inflationary pressures through pricing strategies [81][82] Question: What is the long-term growth outlook for the Biologics segment? - The long-term growth outlook for the Biologics segment remains at 10% to 15%, with significant capacity additions expected to support this growth [12][90]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36587 CATALENT, INC. (Exact name of registrant as specified in its charter) Delaware 20-8737688 (State or other jurisdiction of incorporation or org ...

Q4'22 Earnings Call Presentation August 29, 2022 Agenda Alessandro Maselli, President & Chief Executive Officer • FY'22 & Q4'22 highlights • New operating structure & long-term revenue growth rates • Proposed acquisition of Metrics Contract Services Thomas Castellano, Senior VP & Chief Financial Officer • Q4'22 financial performance • Capitalization review • Guidance Question & Answer Session 2 Disclaimer Statement Forward-Looking Statements This release contains both historical and forward-looking statemen ...

Catalent, Inc. (NYSE:CTLT) Q3 2022 Earnings Conference Call May 3, 2022 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations John Chiminski - Chair and Chief Executive Officer Alessandro Maselli - President and Chief Operating Officer Thomas Castellano - Senior Vice President and Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Luke Sergott - Barclays Capital Jacob Johnson - Stephens, Inc. Julia Qin - J.P. Morgan Sean Dodge - RBC Capital Markets ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |----------------------------------------------------------------------------|---------------------------- ...

Q3'22 Earnings Call Presentation May 3, 2022 Agenda John Chiminski, Chair & Chief Executive Officer • Q3'22 financial highlights • Corporate Responsibility Alessandro Maselli, President & Chief Operating Officer • Operational highlights Thomas Castellano, Senior VP & Chief Financial Officer • Q3'22 financial performance • Capitalization review • Guidance Question & Answer Session 2 Disclaimer Statement Forward-Looking Statements This release contains both historical and forward-looking statements. All state ...

Catalent, Inc. (NYSE:CTLT) Q2 2022 Results Earnings Conference Call February 1, 2022 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations John Chiminski - Chair and Chief Executive Officer Alessandro Maselli - President and Chief Operating Officer Thomas Castellano - Senior Vice President and Chief Financial Officer Conference Call Participants David Windley - Jefferies Tejas Savant - Morgan Stanley Jacob Johnson - Stephens, Inc. Luke Sergott - Barclays Capital Sean Dodge - RBC C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) _____________________________ Catalent, Inc. (Exact name of registrant as specifie ...